Literature Collection

Magnifying Glass
Collection Insights

13K+

References

11K+

Articles

1700+

Grey Literature

4800+

Opioids & SU

The Literature Collection contains over 13,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Enter Search Term(s)
Year
Sort by
Order
Show
13393 Results
2181
Buprenorphine-Based Regimens and Methadone for the Medical Management of Opioid Dependence: Selecting the Appropriate Drug for Treatment
Type: Journal Article
Authors: Icro Maremmani, Gilberto Gerra
Year: 2010
Topic(s):
Opioids & Substance Use See topic collection
2182
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives
Type: Journal Article
Authors: P. Mannelli, K. S. Peindl, T. Lee, K. S. Bhatia, L. T. Wu
Year: 2012
Publication Place: United Arab Emirates
Abstract: Constant refinement of opioid dependence (OD) therapies is a condition to promote treatment access and delivery. Among other applications, the partial opioid agonist buprenorphine has been studied to improve evidence-based interventions for the transfer of patients from opioid agonist to antagonist medications. This paper summarizes PubMed-searched clinical investigations and conference papers on the transition from methadone maintenance to buprenorphine and from buprenorphine to naltrexone, discussing challenges and advances. The majority of the 26 studies we examined were uncontrolled investigations. Many small clinical trials have demonstrated the feasibility of in- or outpatient transfer to buprenorphine from low to moderate methadone doses (up to 60-70 mg). Results on the conversion from higher methadone doses, on the other hand, indicate significant withdrawal discomfort, and need for ancillary medications and inpatient treatment. Tapering high methadone doses before the transfer to buprenorphine is not without discomfort and the risk of relapse. The transition buprenorphine-naltrexone has been explored in several pilot studies, and a number of treatment methods to reduce withdrawal intensity warrant further investigation, including the co-administration of buprenorphine and naltrexone. Outpatient transfer protocols using buprenorphine, and direct comparisons with other modalities of transitioning from opioid agonist to antagonist medications are limited. Given its potential salience, the information gathered should be used in larger clinical trials on short and long-term outcomes of opioid agonist-antagonist transition treatments. Future studies should also test new pharmacological mechanisms to help reduce physical dependence, and identify individualized approaches, including the use of pharmacogenetics and long-acting opioid agonist and antagonist formulations.
Topic(s):
Opioids & Substance Use See topic collection
2183
Buprenorphine-Naloxone Maintenance and Lactation
Type: Journal Article
Authors: L. M. Jansson, K. McConnell, M. Velez, N. Spencer, M. Gomonit, M. J. Swortwood
Year: 2024
Abstract:

BACKGROUND: Breastfeeding among lactating people with opioid use disorder taking buprenorphine monotherapy is generally accepted, as low concentrations of buprenorphine and metabolites in human milk have been well-established. The use of buprenorphine-naloxone for pregnant and lactating people with opioid use disorder is expanding and there is no information available regarding the concentrations of naloxone and their metabolites in human milk to recommend the use of this combination medication during lactation. RESEARCH AIMS: To determine the concentrations of buprenorphine and naloxone and their primary metabolites in human milk, maternal plasma, and infant plasma, among lactating buprenorphine-naloxone maintained people and their infants. METHODS: Four lactating buprenorphine-naloxone maintained people provided plasma and human milk samples on Days 2, 3, 4, 14, and 30 postpartum. Infant plasma was obtained on Day 14. RESULTS: Concentrations of buprenorphine, norbuprenorphine and their glucuronide metabolites were present in maternal plasma and human milk at low concentrations, consistent with previous research in lactating buprenorphine monotherapy participants. Naloxone was not detected, or was detected at concentrations below the limit of quantification, in maternal plasma and in all except one human milk sample at Day 30. Naloxone was not detected or detected at concentrations below the limit of quantification in all infant plasma samples. CONCLUSION: Results support the use of buprenorphine-naloxone by lactating people who meet appropriate criteria for breastfeeding.

Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
Reference Links:       
2186
Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
Type: Journal Article
Authors: M. M. Kanervo, S. J. Tupola, E. M. Nikkola, K. M. Rantakari, H. K. Kahila
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
,
Measures See topic collection
2187
Buprenorphine: new treatment of opioid addiction in primary care
Type: Journal Article
Authors: M. Kahan, A. Srivastava, A. Ordean, S. Cirone
Year: 2011
Publication Place: Canada
Abstract: OBJECTIVE: To review the use of buprenorphine for opioid-addicted patients in primary care. QUALITY OF EVIDENCE: The MEDLINE database was searched for literature on buprenorphine from 1980 to 2009. Controlled trials, meta-analyses, and large observational studies were reviewed. MAIN MESSAGE: Buprenorphine is a partial opioid agonist that relieves opioid withdrawal symptoms and cravings for 24 hours or longer. Buprenorphine has a much lower risk of overdose than methadone and is preferred for patients at high risk of methadone toxicity, those who might need shorter-term maintenance therapy, and those with limited access to methadone treatment. The initial dose should be given only after the patient is in withdrawal. The therapeutic dose range for most patients is 8 to 16 mg daily. It should be dispensed daily by the pharmacist with gradual introduction of take-home doses. Take-home doses should be introduced more slowly for patients at higher risk of abuse and diversion (eg, injection drug users). Patients who fail buprenorphine treatment should be referred for methadone- or abstinence-based treatment. CONCLUSION: Buprenorphine is an effective treatment of opioid addiction and can be safely prescribed by primary care physicians.
Topic(s):
General Literature See topic collection
2189
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)
Type: Journal Article
Authors: J. S. Potter, E. N. Marino, M. P. Hillhouse, S. Nielsen, K. Wiest, C. P. Canamar, J. A. Martin, A. Ang, R. Baker, A. J. Saxon, W. Ling
Year: 2013
Publication Place: United States
Abstract: OBJECTIVE: The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector or non-injector) of opioid use. METHOD: A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. RESULTS: Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated injectors from non-injectors. Further, injectors were more likely to be using at end of treatment compared with non-injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-injectors were more likely than injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. CONCLUSIONS: Findings indicate that substance use severity differentiates heroin users from OA users and injectors from non-injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
Topic(s):
Opioids & Substance Use See topic collection
2190
Buprenorphine/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People
Type: Journal Article
Authors: Kate M. Lillie, Jennifer Shaw, Kelley J. Jansen, Michelle M. Garrison
Year: 2021
Publication Place: Baltimore, Maryland
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
2191
Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments
Type: Journal Article
Authors: K. D. Stone, K. Scott, B. R. Holroyd, E. Lang, K. Yee, N. Taghizadeh, J. Deol, K. Dong, J. Fanaeian, M. Ghosh, K. Low, M. Ross, R. Tanguay, P. Faris, N. Day, P. McLane
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
2192
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Type: Journal Article
Authors: Lynn E. Sullivan, Brent A. Moore, Marek C. Chawarski, Michael V. Pantalon, Declan Barry, Patrick G. O'Connor, Richard S. Schottenfeld, David A. Fiellin
Year: 2008
Topic(s):
Opioids & Substance Use See topic collection
2193
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals
Type: Journal Article
Authors: F. D. Law, A. M. Diaper, J. K. Melichar, S. Coulton, D. J. Nutt, J. S. Myles
Year: 2017
Publication Place: United States
Abstract: Buprenorphine/naloxone, methadone and lofexidine are medications with utility in the treatment of opiate withdrawal. We report the first randomised controlled trial to compare the effects of these two medications on withdrawal symptoms and outcome during opiate induction/stabilisation and detoxification. A double-blind randomised controlled trial was conducted in an outpatient satellite clinic of a specialist drug service. Eighty opiate dependent individuals meeting DSM-IV criteria for opiate dependence, using (1/2) g heroin smoked/chased or (1/4) g heroin injected or 30mg methadone, with 3 years of opioid dependency, underwent a short-term opiate treatment programme involving induction/stabilisation on methadone 30mg or buprenorphine/naloxone 4mg/1mg, followed by detoxification (where the methadone group was assisted by lofexidine). The main outcome measures were urine drug screens for opiates and withdrawal and craving questionnaires. There were no overall differences in positive urine drug screens and drop-outs during any phase of the study. During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group ( p<0.05, 95% confidence interval -3.5, -0.38). During detoxification, withdrawal symptoms were significantly greater and the peak of withdrawal was earlier for the methadone/lofexidine group than the buprenorphine/naloxone group ( p<0.01, 95% confidence interval 3.0, 8.3). Methadone/lofexidine and buprenorphine/naloxone had comparable outcomes during rapid outpatient stabilisation and detoxification in low dose opiate users.
Topic(s):
Opioids & Substance Use See topic collection
2194
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals
Type: Journal Article
Authors: F. D. Law, A. M. Diaper, J. K. Melichar, S. Coulton, D. J. Nutt, J. S. Myles
Year: 2017
Publication Place: United States
Abstract: Buprenorphine/naloxone, methadone and lofexidine are medications with utility in the treatment of opiate withdrawal. We report the first randomised controlled trial to compare the effects of these two medications on withdrawal symptoms and outcome during opiate induction/stabilisation and detoxification. A double-blind randomised controlled trial was conducted in an outpatient satellite clinic of a specialist drug service. Eighty opiate dependent individuals meeting DSM-IV criteria for opiate dependence, using (1/2) g heroin smoked/chased or (1/4) g heroin injected or 30mg methadone, with 3 years of opioid dependency, underwent a short-term opiate treatment programme involving induction/stabilisation on methadone 30mg or buprenorphine/naloxone 4mg/1mg, followed by detoxification (where the methadone group was assisted by lofexidine). The main outcome measures were urine drug screens for opiates and withdrawal and craving questionnaires. There were no overall differences in positive urine drug screens and drop-outs during any phase of the study. During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group ( p<0.05, 95% confidence interval -3.5, -0.38). During detoxification, withdrawal symptoms were significantly greater and the peak of withdrawal was earlier for the methadone/lofexidine group than the buprenorphine/naloxone group ( p<0.01, 95% confidence interval 3.0, 8.3). Methadone/lofexidine and buprenorphine/naloxone had comparable outcomes during rapid outpatient stabilisation and detoxification in low dose opiate users.
Topic(s):
Opioids & Substance Use See topic collection
2195
Burden and nutritional deficiencies in opiate addiction- systematic review article
Type: Journal Article
Authors: S. Nabipour, Ayu Said, Hussain Habil
Year: 2014
Publication Place: Iran
Abstract: Addiction to the illicit and prescribed use of opiate is an alarming public health issue. Studies on addictive disorders have demonstrated severe nutritional deficiencies in opiate abusers with behavioral, physiological and cognitive symptoms. Opiate addiction is also link with a significant number of diseases including Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and other blood borne diseases generally stem from the use of needles to inject heroin. The use of medication assisted treatment for opioid addicts in combination with behavioural therapies has been considered as a highly effective treatment. Methadone is a long-lasting mu-opioid agonist and a pharmacological tool which attenuates withdrawal symptoms effectively replacement therapies. This review article aims to explain opiate addiction mechanisms, epidemiology and disease burden with emphasis on dietary and nutritional status of opiate dependent patients in methadone maintenance therapy.
Topic(s):
Opioids & Substance Use See topic collection
2196
Burden of geriatric and cognitive disorders and the impact of integrated care models on morbidity, functional decline, and health service utilization among older adults
Type: Journal Article
Authors: L. Chai, N. Gou
Year: 2026
Abstract:

BACKGROUND: The health conditions of elderly people who have multiple chronic illnesses and geriatric syndromes lead to severe health problems, which result in decreased ability to function and increased need for medical services. METHODS: The study used a retrospective cohort design with propensity score matching and multivariable modeling to examine the impact of different care models on outcomes over a 24-month period. Five outcomes including hospitalization rates and functional decline rates through ADL and IADL assessments, cognitive decline rates, mortality rates, and service usage rates. RESULTS: The matching process achieved balanced baseline characteristics between groups because SMD measurements stayed below 0.05. Geriatric syndromes had high prevalence rates with 40.0% cognitive impairment, 32.0% frailty, 32.5% depression, 49.0% polypharmacy, and 68.5% multimorbidity. The health service utilization showed substantial levels, which included 92 hospital admissions per 100 person-years and 134 emergency visits per 100 person-years. 31.4% of participants experienced functional decline in activities of daily living ADL and 42.7% suffered a similar decline in instrumental activities of daily living IADL while EQ-5D showed quality-of-life deterioration of -0.04. Integrated care provided benefits which decreased hospital admissions (IRR 0.78, 95% CI 0.71-0.87) and 30-day readmissions (OR 0.81) and reduced length of stay (-1.2 days). Cognitive decline underwent partial protection (MoCA change +0.86; dementia conversion HR 0.71), and mortality decreased (HR 0.76). Multivariable models show that frailty (OR 2.21) and cognitive impairment (OR 1.42) served as strong predictors of functional decline. The protective effects of integrated care continued to exist (OR 0.81). Mediation analysis suggested that approximately 25% of the observed advantage came from reduced frailty. CONCLUSION: Older adults exhibit high burdens of geriatric syndromes and healthcare utilization, which leads to their functional and cognitive decline. Integrated care models reduce hospital admissions and delay cognitive decline while increasing patient survival because they help manage frailty and provide unified treatment.

Topic(s):
Healthcare Disparities See topic collection
2197
Burden of medical illness in drug- and alcohol-dependent persons without primary care
Type: Journal Article
Authors: I. De Alba, J. H. Samet, R. Saitz
Year: 2004
Topic(s):
General Literature See topic collection
2198
Burden of obesity in local health systems: A comparative analysis across three integrated care boards in England with a focus on type 2 diabetes
Type: Journal Article
Authors: A. Zafar, C. Scarlata
Year: 2026
Abstract:

AIMS: To estimate and compare the economic burden of obesity across three Integrated Care Boards in England, with a specific focus on the contribution of Type 2 diabetes and related complications. METHODS: An adapted burden of obesity model integrating estimated national health costs data with local population metrics was applied to the integrated care boards to estimate health care, social care, productivity and economic and quality of life associated costs. Data were stratified by sector, age, sex, BMI and prevalence of obesity-related complications. RESULTS: Across the regions, 599,248 adults were living with obesity. Total economic burden reflected obesity prevalence, with the highest costs in Leicester, Leicestershire and Rutland, followed by Bedfordshire, Luton and Milton Keynes and then Northamptonshire. Despite this, Bedfordshire, Luton and Milton Keynes had the highest per-patient costs across all cost categories. Social care and productivity losses each contributed approximately 30% of total costs, with informal care comprising 96% of social care expenditure. Per-patient healthcare costs increased with BMI. Type 2 diabetes and hypertension were among the most prevalent and costly complications, while stroke and coronary heart disease had the highest per-patient costs. Coexisting coronary heart disease with Type 2 diabetes significantly increased treatment costs. Obesity was more prevalent among working-age adults, with males incurring higher per-patient complication costs across all conditions and integrated care boards. CONCLUSIONS: This study demonstrates the significant and variable local economic burden of obesity. Disparities in per-patient costs, sex and complication profiles highlight the need for stratified, data-driven commissioning. Targeted prevention in high-burden areas can help ICBs reduce system pressures and guide effective local strategies.

Topic(s):
Financing & Sustainability See topic collection
2199
Burnout among behavioral health providers in integrated care settings
Type: Journal Article
Authors: M. Zubatsky, C. Runyan, S. Gulotta, J. R. Knight, J. D. Pettinelli
Year: 2020
Publication Place: United States
Topic(s):
Education & Workforce See topic collection
,
Measures See topic collection
2200
Burnout and Well-Being Among Nurses in an Integrated Healthcare System
Type: Journal Article
Authors: H. J. Kim, L. O. Pole, C. P. Ramirez, B. Simons, M. Mancuso, N. VanderHorst, R. Merizian, T. B. Moore, M. Dee, P. Doulaveris, L. N. Kawar
Year: 2026
Abstract:

Background/local problem : An integrated healthcare system conducted surveys to assess overall well-being to describe perceptions of work environment and to inform meaningful intervention. Burnout and high turnover are compromising workplace safety and quality of care. METHODS: Surveys were sent to all eligible employees in the organization and participation was voluntary and confidential. The 2022 surveys were conducted, and 6,913 nurses participated. INTERVENTIONS: Statistical testing was conducted to identify demographic differences in burnout for tenure, age, manager/non-manager, and care setting. Regressions were conducted to determine top predictors of burnout. RESULTS: Significant differences were found in tenure ( P < .001), age ( P < .001), and manager/ non-manager ( P = .009). Mental health, retention, and workload significantly predicted burnout, F (3,4609) = 1028.33, P < .001, R2 adj = 0.40. CONCLUSION: Nursing burnout ultimately affects turnover and retention in a healthcare system. Monitoring by age, tenure, manager status, and care setting are vital for addressing burnout for nurses.

Topic(s):
Education & Workforce See topic collection